Medical Technology Cost Awareness “Campaign” Led By Blues, Lewin Report
This article was originally published in The Gray Sheet
Executive Summary
The BlueCross BlueShield Association intends to heighten consumer awareness of accelerating medical technology costs, which the group believes is a key driver of U.S. health expenditures in recent years
You may also be interested in...
Health Affairs Study Deflects New Tech Cost Critics; JEC Report Forthcoming
An article in the 1July/August issue of Health Affairs cites economic data from FDA Commissioner Mark McClellan to argue that thwarted access to new medical technologies among the uninsured yields $1.1 bil. in lost annual net benefits
Health Affairs Study Deflects New Tech Cost Critics; JEC Report Forthcoming
An article in the 1July/August issue of Health Affairs cites economic data from FDA Commissioner Mark McClellan to argue that thwarted access to new medical technologies among the uninsured yields $1.1 bil. in lost annual net benefits
FDA Will Play Supporting Role, Not Preside Over Cost-Effectiveness Criteria
The growing call for greater federal cost-effectiveness evaluation of new medical technologies will not alter FDA's primary focus on risk-benefit analysis